Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0
|
作者：
Dholaria, Bhagirathbhai R.
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Martin, Thomas G.
Morillo, Daniel
Reece, Donna Ellen
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar J.
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, Marie-Anne Damiette
Wasch, Ralph
van de Donk, Niels W. C. J.
Chari, Ajai
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Univ Hosp Salamanca, Salamanca, Spain
[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA
[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[11] Med Coll Wisconsin, Milwaukee, WI USA
[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[16] Janssen Res & Dev, Spring House, PA USA
[17] Janssen Res & Dev, Antwerp, Belgium
[18] Janssen Biol Europe, Leiden, Netherlands
[19] Freiburg Univ, Med Ctr, Freiburg, Germany
[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[21] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8003
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM).
    Shank, Brandon R.
    Primeaux, Brian
    Horowitz, Sandra B.
    Yeung, Erin K.
    Lee, Irene Y.
    Kaufman, Gregory Peter
    Lee, Hans Chulhee
    Manasanch, Elisabet Esteve
    Patel, Krina K.
    Orlowski, Robert Z.
    Weber, Donna M.
    Thomas, Sheeba K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA
    Usmani, Saad
    Mateos, Maria-Victoria
    Hungria, Vania
    Iida, Shinsuke
    Bahlis, Nizar J.
    Nahi, Hareth
    Magen, Hila
    Cavo, Michele
    Hulin, Cyrille
    White, Darrell
    De Stefano, Valerio
    Slavcev, Mary
    Heuck, Christoph
    Qin, Xiang
    Masterson, Tara
    Lantz, Kristen
    Gries, Katharine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E247 - E248
  • [23] First Results From the RedirecTT-1 Study With Teclistamab (Tec) plus Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    Cohen, Yael
    Morillo, Daniel
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Oriol, Albert
    Ocio, Enrique
    Yoon, Sung-Soo
    Mateos, Maria-Victoria
    Chu, Michael
    Rodriguez-Otero, Paula
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Guo, Yue
    Krevvata, Maria
    Peterson, Michelle
    Beelen, Melissa
    Vanak, Jill
    Banerjee, Arnob
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S478 - S479
  • [24] HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Norkin, Maxim
    Blade, Joan
    Cavo, Michele
    Hassoun, Hani
    Leleu, Xavier
    Alegre, Adrian
    Maisel, Christopher
    Paner, Agne
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Puig, Noemi
    Harran, John
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S329 - S330
  • [25] Daratumumab-Based Regimens with Prior Carfilzomib in Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Tungesvik, Alexandre
    Huang, Jessica
    Sudalagunta, Praneeth
    Dimaggio, Elizabeth
    De Avila, Gabe
    Tandon, Ankita
    Nelson, Rebeccah
    Olson, Laura
    Tobon, Katherine
    Shain, Kenneth
    Brayer, Jason
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S327 - S328
  • [26] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
    Schinke, C.
    Touzeau, C.
    Minnema, M. C.
    van de Donk, N. W.
    Rodriguez-Otero, P.
    Mateos, M. -V.
    Rasche, L.
    Ye, J. C.
    Vishwamitra, D.
    Ma, X.
    Qin, X.
    Campagna, M.
    Masterson, T.
    Hilder, B.
    Tolbert, J.
    Renaud, T.
    Goldberg, J.
    Heuck, C.
    Chari, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
  • [27] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
    Mateos, Maria-Victoria
    Blade, Joan
    Larocca, Alessandra
    Oriol, Albert
    Rodriguez, Paula
    Alegre, Adrian
    Cavo, Michele
    Moreb, Jan S.
    Paner, Agne
    Gabrail, Nashat
    Halka, Kathleen G.
    Hassoun, Hani
    Maisel, Christopher
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Ocio, Enrique M.
    Byrne, Catriona
    Harmenberg, Johan
    Thuresson, Sara
    Nordstrom, Eva
    Lindberg, Jakob
    Richardson, Paul G.
    BLOOD, 2017, 130
  • [28] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
    Schinke, Carolina D.
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Rasche, Leo
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Ma, Xuewen
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara J.
    Hilder, Brandi
    Tolbert, Jaszianne A.
    Renaud, Thomas
    Goldberg, Jenna
    Heuck, Christoph
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
    Chari, Ajai
    Usmani, Saad Zafar
    Mateos, Maria-Victoria
    Van De Donk, Niels
    Kaufman, Jonathan L.
    Moreau, Philippe
    Rocafiguera, Albert Oriol
    Plesner, Torben
    Benboubker, Lotfi
    Liu, Kevin
    Hellemans, Peter
    Masterson, Tara J.
    Clemens, Pamela L.
    Farnsworth, Andrew
    Nahi, Hareth
    San-Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)
    Yimer, Habte
    Melear, Jason
    Faber, Edward
    Bensinger, William
    Burke, John M.
    Narang, Mohit
    Stevens, Don
    Gunawardena, Sriya W.
    Lutska, Yana
    Qi, Keqin
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas
    Rifkin, Robert M.
    BLOOD, 2018, 132
12345